Cite
Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.
MLA
Shih, I.Hung, et al. “Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase.” Antimicrobial Agents and Chemotherapy, vol. 55, no. 9, Sept. 2011, pp. 4196–203. EBSCOhost, https://doi.org/10.1128/AAC.00307-11.
APA
Shih, I.-H., Vliegen, I., Peng, B., Yang, H., Hebner, C., Paeshuyse, J., Pürstinger, G., Fenaux, M., Tian, Y., Mabery, E., Qi, X., Bahador, G., Paulson, M., Lehman, L. S., Bondy, S., Tse, W., Reiser, H., Lee, W. A., Schmitz, U., … Zhong, W. (2011). Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrobial Agents and Chemotherapy, 55(9), 4196–4203. https://doi.org/10.1128/AAC.00307-11
Chicago
Shih, I-Hung, Inge Vliegen, Betty Peng, Huiling Yang, Christy Hebner, Jan Paeshuyse, Gerhard Pürstinger, et al. 2011. “Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase.” Antimicrobial Agents and Chemotherapy 55 (9): 4196–4203. doi:10.1128/AAC.00307-11.